Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Decoy Therapeutics Inc (DCOY)

Decoy Therapeutics Inc (DCOY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing PR Newswire - Fri Jun 26, 7:11PM CDT

HOUSTON , June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category...

DCOY : 7.31 (-4.07%)
Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London PR Newswire - Mon Jun 8, 7:00AM CDT

Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development

DCOY : 7.31 (-4.07%)
Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors PR Newswire - Wed Jun 3, 7:00AM CDT

CAMBRIDGE, Mass. , June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered...

DCOY : 7.31 (-4.07%)
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic PR Newswire - Mon Jun 1, 6:00AM CDT

Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic

DCOY : 7.31 (-4.07%)
Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board PR Newswire - Tue May 26, 7:15AM CDT

Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development

DCOY : 7.31 (-4.07%)
Decoy Therapeutics: Q1 Earnings Snapshot AP - Fri May 8, 3:53PM CDT

Decoy Therapeutics: Q1 Earnings Snapshot

DCOY : 7.31 (-4.07%)
Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston PR Newswire - Mon Apr 27, 7:45AM CDT

CBO Peter Marschel to Lead HubXchange Roundtable on Computational Peptide Design

DCOY : 7.31 (-4.07%)
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline PR Newswire - Thu Apr 9, 7:36AM CDT

Highly differentiated AI-powered D-MAV discovery platform targeting drug discovery in the multi-billion-dollar antiviral markets

DCOY : 7.31 (-4.07%)
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 PR Newswire - Mon Apr 6, 8:15AM CDT

Live video webcast with Rick Pierce, Chief Executive Officer of Decoy Therapeutics, on Thursday, April 9 th at 4:00 PM ET

DCOY : 7.31 (-4.07%)
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire - Thu Apr 2, 8:00AM CDT

CAMBRIDGE, Mass. and HOUSTON , April 2, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from...

DCOY : 7.31 (-4.07%)

Barchart Exclusives

Nike Beat Wall Street Estimates by a Mile. Why Investors Are Still Not Convinced. Barchart - 55 minutes ago
Nike crushed Wall Street's expectations, but investors remain focused on a turnaround that is still far from complete. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.